Prof.Dr.Sci.Hamza Mujagic, MD.Ph.D. is former Visiting Scholar at Massachusetts General Hospital Cancer Center/ Harvard University/, Clinical Review Board Member for Harvard University Cancer Center, Boston and former Consultant for Xanthus Pharmaceuticals, Cambridge, Massachusetts, USA. He graduated from the University of Zagreb Medical School in 1968 where he also received his basic clinical training and Board certification in Medicine. He obtained his Master's degree from the Center of Advanced Postgraduate Studies, the University of Zagreb in 1973 and his Ph.D. from the Deutsches Krebsforschung Zentrum, University of Essen, Germany and the University of Zagreb in 1976. He received his specialty training in Nuclear Medicine in 1971-1972 and Clinical Oncology in 1972-1977 from Central Institute for tumors in Zagreb and Internal medicine from several clinical centers in Europe and from the University Medical Center in Sarajevo in 1980. He started his career in Translational Medicine as a Fellow of Scientific Foundation of The Republic of Croatia combining his research at Institute Rudjer Boskovic/ University of Zagreb from 1969-1971 and clinical work at University Hospital “Merkur” in1972 and continued his career in translational medicine at Central Institute for tumors in Zagreb from 1971-1977 where he organized the Clinical Tumor Immunology and Pharmacology service.. As a recipient of International Union Against Cancer (ICRETT) Award he worked in the National Cancer Institute/ National Institutes of Health of the USA in Bethesda from 19781979 in the Division of Tumor Immunology. He was then invited to join The National Cancer Institute and worked there from 1980-1984 in the Division of Cancer Treatment and Clinical Cancer Pharmacology Branch. He then accepted a highly competitive position in Department of Cancer Immunology and Immunotherapy at the Memorial Sloan-Kettering Cancer Center, New York, from 1984-1985. He served in leading positions for Clinical Cancer Biology at the Universities in Sarajevo,Banjaluka, and Tuzla. In the year of 1977, he served as a Visiting Professor of Cancer Biology at the Clinic of Oncology of the University Marburg a der Lahn, Germany. He was associated as a Visiting Scholar with Massachusetts General Hospital and Harvard University from 1997 and on, where he has spent most of his last 12 professional years. He is a specialist in Internal Medicine/subspecialties Urologic Oncology and Cancer Pharmacology/ Immunology and is Professor of Medicine and Oncology. He published 107 research papers, is Editor-in-Chief of one international journal, on the Editorial Boards of 9 international journals, reviewer for several scientific journals and is cited thus far 591 times. He is executive vice president of the World Academy of Medical Sciences and on the Core Board of International Academy of Medical Sciences and Marquis Who is Who cited. His areas of expertise are Urologic, lung, breast, GI and melanoma cancers, design and conduct of Clinical Trials, Cancer Chemotherapy and Immunotherapy, and Cancer drug analysis and writing. His latest working engagement was as senior Consultant and Professor at Länssjukhus Sundsvall/Umeå University, Department of Oncology, Sundsvall, Sweden.